Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal
Theravance Biopharma Inc.'s stock (TBPH) tumbled 21% early Friday,ter the biotech said a Phase 4 trial of its Yupelri treatment for patients with severe to very severe Chronic Obstructive Pulmonary Disease, or COPD, failed to meet its main goal. The trial dubled PFIR-2 aimed to show greater improvement in lung function for Yupelri delivered by standard jet nebulizer compared to Spiriva delivered via a dry powder inhaler in adults with COPD. "The study did not show a statistically significant difference betweenYupelri and Spiriva HandiHaler on the primary endpoint, change from baseline in trough forced expiratory volume in one second (FEV1) at Day 85," the company said in a statement. It did however show similar lung function in both arms of the study and showed safety and tolerability that was consistent with earlier studies. YUPELRI is approved in the U.S. for the maintenance treatment of patients with COPD. Spiriva HandiHaler is approved in the U.S. for the long-term, once-daily, maintenance treatment of bronchospasm associated with COPD, and for reducing COPD exacerbations, said the statement. The stock has gained 4% in the last 12 months, while the S&P 500 has gained 23%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-05-24 0615ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
How the Tokyo Stock Exchange Is Pushing for Better Capital Allocation
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting